ArticleFrontiers in public health2020

Health Technology Assessment for Vaccines Against Rare, Severe Infections: Properly Accounting for Serogroup B Meningococcal Vaccination's Full Social and Economic Benefits.

Andrew Stawasz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.